Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Mylan Almost Triples Revenue -- Big Deal

Mylan's (NYSE: MYL  ) revenue spiked 188% year over year last quarter, but I'm not impressed.

Foolish writers rarely get to say such things. Even for high-growth companies like Intuitive Surgical (Nasdaq: ISRG  ) or Onyx Pharmaceuticals (Nasdaq: ONXX  ) , almost tripling revenue is usually considered impressive.

But Mylan's growth was entirely extrinsic, stemming from its acquisition of Matrix in January of last year, and from the subsequent engulfing of Merck KGaA's generic-drug business in October. Those acquisitions -- especially the $6.7 billion all-cash deal for Merck's generics -- came at a cost. Adjusted diluted earnings per share slipped to just $0.11 (from $0.45 per share in the year-ago quarter) because interest expense jumped to $133 million (compared to just $10.5 million the year prior). In addition, the company now has more shares outstanding, since it made a public offering to pay for the acquisitions.

The good news is that Mylan has a plan to get its earnings headed back in the right direction. To save money -- that's what acquisitions are all about, right? -- it's shutting down multiple research and development and manufacturing sites.

More importantly, it's planning to sell off some of its assets to focus on its generic-drug business, and perhaps pay down some of that monster debt load. Yesterday, Mylan announced that it had sold its post-2010 royalties from recently approved Bystolic to partner Forest Labs (NYSE: FRX  ) for $370 million. It's also considering the sale of both Dey, its branded pharmaceutical business, and Docpharma, its operation for Belgium, the Netherlands, and Luxemburg, which it acquired in the recent deals.

Mylan's new larger size should help it compete against the two big guns in generic drugs: Teva Pharmaceutical (Nasdaq: TEVA  ) and Novartis (NYSE: NVS  ) . If it can trim the fat, Mylan should make for a good long-term investment.

More Foolishness that's far from generic:

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 587559, ~/Articles/ArticleHandler.aspx, 10/28/2016 6:00:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,161.19 -8.49 -0.05%
S&P 500 2,126.41 -6.63 -0.31%
NASD 5,190.10 -25.87 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 4:00 PM
MYL $37.19 Down -0.83 -2.18%
Mylan CAPS Rating: ***
FRX.DL $0.00 Down +0.00 +0.00%
Forest Laboratorie… CAPS Rating: ****
ISRG $666.55 Up +3.32 +0.50%
Intuitive Surgical CAPS Rating: ****
NVS $71.07 Down -0.54 -0.75%
Novartis CAPS Rating: ****
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **
TEVA $42.32 Down -0.83 -1.92%
Teva Pharmaceutica… CAPS Rating: ****